These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37276047)

  • 1. Effect of Disease-Modifying Therapies on COVID-19 Vaccination Efficacy in Multiple Sclerosis Patients: A Comprehensive Review.
    Jamali E; Shapoori S; Farrokhi MR; Vakili S; Rostamzadeh D; Iravanpour F; Tavakoli Oliaee R; Jafarinia M
    Viral Immunol; 2023; 36(6):368-377. PubMed ID: 37276047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary of Safety and Efficacy of COVID Vaccination in Patients with Multiple Sclerosis.
    Pernicová E; Macounová P; Krsek M; Maďar R
    Eur Neurol; 2023; 86(4):263-276. PubMed ID: 36871554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy.
    Reder AT; Stuve O; Tankou SK; Leist TP
    Mult Scler; 2023 May; 29(6):648-656. PubMed ID: 36440826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations.
    Pugliatti M; Berger T; Hartung HP; Oreja-Guevara C; Bar-Or A
    Curr Opin Neurol; 2022 Jun; 35(3):319-327. PubMed ID: 35674075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.
    Garjani A; Patel S; Bharkhada D; Rashid W; Coles A; Law GR; Evangelou N
    Mult Scler Relat Disord; 2022 Jan; 57():103458. PubMed ID: 34896876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review.
    Sharifian-Dorche M; Sahraian MA; Fadda G; Osherov M; Sharifian-Dorche A; Karaminia M; Saveriano AW; La Piana R; Antel JP; Giacomini PS
    Mult Scler Relat Disord; 2021 May; 50():102800. PubMed ID: 33578206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
    Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?
    Bellucci G; Rinaldi V; Buscarinu MC; Reniè R; Bigi R; Pellicciari G; Morena E; Romano C; Marrone A; Mechelli R; Salvetti M; Ristori G
    Front Immunol; 2021; 12():755333. PubMed ID: 34646278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
    Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Outcome of COVID-19 in Pediatric-Onset Multiple Sclerosis Patients.
    Oncel I; Alici N; Solmaz I; Oge DD; Ozsurekci Y; Anlar B
    Pediatr Neurol; 2022 Sep; 134():7-10. PubMed ID: 35772229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies.
    Capone F; Lucchini M; Ferraro E; Bianco A; Rossi M; Cicia A; Cortese A; Cruciani A; De Arcangelis V; De Giglio L; Motolese F; Sancetta B; Mirabella M; Di Lazzaro V
    Neurotherapeutics; 2022 Jan; 19(1):325-333. PubMed ID: 34859382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of our understanding of MS-COVID-19 interactions and concerns for vaccination.
    Podury S; Khan E; Tandon M; Jaiswal S; Sriwastava S
    J Clin Neurosci; 2021 Aug; 90():132-134. PubMed ID: 34275536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of disease-modifying drugs on the severity of  COVID-19 infection in multiple sclerosis patients.
    Rostami Mansoor S; Ghasemi-Kasman M
    J Med Virol; 2021 Mar; 93(3):1314-1319. PubMed ID: 33044760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 and MS disease-modifying therapies.
    Berger JR; Brandstadter R; Bar-Or A
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32414755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential Risks and Benefits of Multiple Sclerosis Immune Therapies in the COVID-19 Era: Clinical and Immunological Perspectives.
    Bhise V; Dhib-Jalbut S
    Neurotherapeutics; 2021 Jan; 18(1):244-251. PubMed ID: 33533012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
    Sormani MP; Inglese M; Schiavetti I; Carmisciano L; Laroni A; Lapucci C; Da Rin G; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
    EBioMedicine; 2021 Oct; 72():103581. PubMed ID: 34563483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis.
    Wu X; Wang L; Shen L; Tang K
    EBioMedicine; 2022 Jul; 81():104102. PubMed ID: 35759920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
    Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
    Front Immunol; 2021; 12():781843. PubMed ID: 34956211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination of multiple sclerosis patients during the COVID-19 era: Novel insights into vaccine safety and immunogenicity.
    Kim E; Haag A; Nguyen J; Kesselman MM; Demory Beckler M
    Mult Scler Relat Disord; 2022 Nov; 67():104172. PubMed ID: 36116380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.